Boston Scientific recently began enrollment in a new study – the Intracept Minimally-invasive PROcedure for VErtebrogenic back pain (IMPROVE) – to compile real-world outcomes of patients treated with the next-generation Intracept™ Access Instruments. The IMPROVE Study...
Policy expands physician and patient access for vertebrogenic low back pain treatmentMARLBOROUGH, Mass., Feb. 22, 2024 – Boston Scientific Corporation (NYSE: BSX) has announced that Noridian Healthcare Solutions, a Medicare Administrative Contractor (MAC), published a...
Third national coverage policy published in 2023 for proven vertebrogenic pain treatment MINNEAPOLIS – November 13, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Humana...
Expands access to vertebrogenic pain treatment for 36 million patients MINNEAPOLIS – October 3, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Anthem Blue Cross and Blue...
Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic pain CHICAGO – IPSIS Annual Meeting – September 21, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back...
Findings show marked reductions in need for opioids and therapeutic lumbosacral spine injections five years post-procedure MINNEAPOLIS – September 12, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low...
